Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New anticoagulants: an update.

Mark Crowther1, Jeffrey I Weitz

  • 1Division of Hematology, St. Joseph's Hospital, McMaster University, Hamilton, Ontario, Canada.

Clinical Advances in Hematology & Oncology : H&O
|September 21, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aspirin Dosing Frequency and Dose Influence Thromboxane Suppression Despite Uniform Inhibition of Arachidonic Acid-induced Platelet Aggregation.

TH open : companion journal to thrombosis and haemostasis·2026
Same author

Poly(sulfobetaine-<i>co</i>-oligoethylene Glycol Methyl Ether Methacrylate) Copolymers with Improved Anti-Fouling and Anti-Coagulant Properties.

Biomacromolecules·2026
Same author

A novel biosensor for measuring plasmin activity.

Research and practice in thrombosis and haemostasis·2026
Same author

Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in AZALEA-TIMI 71.

Blood·2026
Same author

Long-Term Hydrophilic, Anti-Clotting, and Anti-Fibrotic Dynamic Covalent Silicone-Based Biomaterials.

Advanced healthcare materials·2026
Same author

Pharmacologic Factor XI/XIa Inhibitors: What the Laboratory Hematologist Needs to Know.

Clinics in laboratory medicine·2026
Same journal

Clinical response with cabozantinib plus nivolumab, a first-line therapy in advanced renal cell carcinoma: a clinical case report.

Clinical advances in hematology & oncology : H&O·2026
Same journal

Active treatment in high-risk, early-stage CLL or SLL.

Clinical advances in hematology & oncology : H&O·2026
Same journal

Targeting human kallikrein 2 in prostate cancer.

Clinical advances in hematology & oncology : H&O·2026
Same journal

Targeting BRAF V600E mutations in metastatic colorectal cancer.

Clinical advances in hematology & oncology : H&O·2026
Same journal

The development of second-generation KRAS inhibitors.

Clinical advances in hematology & oncology : H&O·2026
Same journal

Clinical applications of PARP inhibitors in breast, ovarian, and prostate cancer: current insights and future directions.

Clinical advances in hematology & oncology : H&O·2026
See all related articles

New anticoagulants offer improved options over traditional treatments like heparin and vitamin K antagonists. This review highlights novel drugs targeting blood coagulation for streamlined anticoagulant therapy.

Area of Science:

  • Pharmacology
  • Thrombosis Research
  • Drug Development

Background:

  • Recent years have seen a significant increase in the development of anticoagulant medications.
  • New parenteral anticoagulants aim to address limitations associated with heparin and low molecular weight heparin.
  • Novel oral anticoagulants are being developed for more convenient anticoagulant therapy compared to vitamin K antagonists.

Purpose of the Study:

  • To review new anticoagulants in advanced clinical testing.
  • To identify the molecular targets of these emerging anticoagulant drugs.
  • To summarize clinical trial results and discuss future opportunities for anticoagulants.

Main Methods:

  • Literature review focusing on anticoagulants in late-stage clinical trials.

Related Experiment Videos

  • Identification of molecular targets for novel anticoagulant agents.
  • Analysis of published clinical trial data for efficacy and safety.

    • Main Results:

    • Several new parenteral and oral anticoagulants targeting specific factors in the coagulation cascade are in advanced development.
    • Clinical trials indicate potential for improved efficacy and safety profiles compared to existing therapies.
    • The review identifies key molecular targets including Factor Xa and direct thrombin inhibitors.

    Conclusions:

    • New anticoagulants represent a significant advancement in managing thrombotic and bleeding disorders.
    • These novel agents offer the potential for more targeted and streamlined anticoagulant therapy.
    • Further research and clinical application will define the ultimate role of these anticoagulants in patient care.